Zapnometinib

DB18244InvestigationalSmall molecule

Zapnometinib: Overview.

Mechanism: Pharmacologically active on Dual specificity mitogen-activated protein kinase kinase 2 and Mitogen-activated protein kinase kinase (MAPKK)
Curator reviewed
Formula / weight: C₁₃H₇ClF₂INO₂ · 409.56 g/mol (avg)
Also known as: Benzoic acid, 2-((2-chloro-4-iodophenyl)amino)-3,4-difluoro-
Code names: ATR-002 · PD-0184264

Resolves to

Compound

Structure

InChIKeyXCNBGWKQXRQKSA-UHFFFAOYSA-NSMILESOC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1Cl

Targets

What you can answer from here — as of July 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zapnometinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.